Oncoinfo· @Oncoinfo_it · X·· 12 小时前评分70
正文 · 机器翻译
#ESMO26 | Izalontamab brengitecan 适用于既往治疗的 HR+/HER- 晚期复发性或转移性乳腺癌：这种新型 ADC 的疗效明确，但真正的关键问题其实是…… 🤔
Armando Orlandi 谈 PANKU-Breast01👇
#OncoSTEPS #metastaticbreastcancer #mBC #ADCs
18 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA50按 Proffered paper 1: Breast cancer, early and advanced stage 对上
PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
https://esmocongress.esmo.org来源：Oncoinfo · x.com